Impact of the ONCOBIOME network in cancer microbiome research

Zitvogel L, Derosa L, Routy B, Loibl S, Heinzerling L, Heinzerling L, de Vries IJM, Engstrand L, Zeller G, Trochon JJ, Trinchieri G, Sow C, Szallasi Z, Schuler G, Schuler-Thurner B, Tarallo S, Rachid MH, Popovici V, Pizzato E, Piccinno G, Pinto F, Pardini B, Naccarati A, Monville F, Messaoudene M, Martineau M, Lehtio J, Iebba V, Guindo CO, Gariboldi M, Gaborit J, Fidelle M, Ferrere G, Felder B, Fall K, Elkrief A, Eisinger F, Ehrlich S, Durand S, Denkert C, Daillère R, Cremolini C, Cordero F, Caldas C, Budinska E, Brusselaers N, Bol K, Boleij A, Barbieri D, Silva CAC, Segata N, Kroemer G (2025)

Publication Type: Journal article, Review article

Publication year: 2025

Journal

Article Number: 1633

DOI: 10.1038/s41591-025-03608-8

Abstract

The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.

Authors with CRIS profile

Involved external institutions

Institut Gustave-Roussy France (FR) Université de Montréal Canada (CA) Goethe-Universität Frankfurt am Main Germany (DE) Klinikum der Universität München (LMU Klinikum) Germany (DE) Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC) Netherlands (NL) Karolinska Institute Sweden (SE) European Molecular Biology Laboratory (EMBL) Germany (DE) Danish Cancer Society Research Center Denmark (DK) Istituto Italiano per la Medicina Genomica / Italian Institute for Genomic Medicine (IIGM) Italy (IT) Masaryk University Czech Republic (CZ) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) University of Cambridge United Kingdom (GB) UNICANCER Group France (FR) Università degli Studi di Trento Italy (IT) Centre de Recherche des Cordeliers France (FR) Veracyte United States (USA) (US) Institute Paoli-Calmettes France (FR) Fondazione IRCCS: Istituto Nazionale dei Tumori Italy (IT) Everimmune France (FR) GBG Forschungs GmbH (German Breast Group) Germany (DE) King’s College London United Kingdom (GB) Philipps-Universität Marburg Germany (DE) University of Pisa / Università di Pisa (UniPi) Italy (IT)

How to cite

APA:

Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., Heinzerling, L.,... Kroemer, G. (2025). Impact of the ONCOBIOME network in cancer microbiome research. Nature Medicine. https://doi.org/10.1038/s41591-025-03608-8

MLA:

Zitvogel, Laurence, et al. "Impact of the ONCOBIOME network in cancer microbiome research." Nature Medicine (2025).

BibTeX: Download